KRYS News and Press, Krystal Biotech Inc. From 07/01/19

PITTSBURGH, July 01, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat skin diseases, today announces that it has been added to the Russell 2000 ®  Index, effective after the stock mark...

Krystal Biotech (NASDAQ: KRYS ) has priced its public offering of 2.5M common shares at $40/share, for gross proceeds of ~$100M. More news on: Krystal Biotech, Inc., Healthcare stocks news, Read more ...

PITTSBURGH, June 24, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has priced the...

PITTSBURGH, June 24, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has commenced ...

Gainers:  VivoPower International (NASDAQ: VVPR ) +108% . Minerva Neurosciences (NASDAQ: NERV ) +43% . PCM (NASDAQ: PCMI ) +42% . Krystal Biotech (NASDAQ: KRYS ) +30% . NRC Group Holdings (NYSEMKT: NRCG ) +26% . India Globalization Capital (NYSEMKT: IGC ) +21% . Rekor Systems (R...

Thinly traded Krystal Biotech ( KRYS +26.8% ) is up on more than triple normal volume, albeit on turnover of only 370K shares, on the heels of positive data from a Phase 2 clinical trial, GEM-2, evaluating topical gene therapy candidate KR103 in patients with a rare inherited skin disord...

Minerva Neurosciences (NASDAQ: NERV ) +58%  on positive results from a Phase 2b clinical trial,  ISM2005 , evaluating seltorexant (MIN-202) in patients with insomnia disorder. More news on: Minerva Neurosciences, Inc., PCM, Inc., Krystal Biotech, Inc., Stocks on the move, ...

Safety data from all patients show that KB103 was well tolerated with no adverse events reported Five out of six wounds treated with KB103 in the Phase 2 trial closed 100% during the trial The average time to complete 100% wound closure on KB103 treated wounds in Phase 2 trial was 2...

KB105 is a new gene therapy candidate engineered with a Transglutaminase-1 (TGM1) gene construct to treat TGM1 deficient autosomal recessive congenital ichthyosis KB105 is the second pipeline product based on the STAR-D platform and is part of a growing pipeline of gene therapy candid...

The following slide deck was published by Krystal Biotech, Inc. in conjunction with this Read more ...